Allogene Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.20 Insider Own3.50% Shs Outstand141.36M Perf Week0.51%
Market Cap1.67B Forward P/E- EPS next Y-2.87 Insider Trans1.81% Shs Float80.10M Perf Month49.43%
Income-303.80M PEG- EPS next Q-0.69 Inst Own64.70% Short Float27.54% Perf Quarter24.44%
Sales0.20M P/S8362.54 EPS this Y9.00% Inst Trans6.46% Short Ratio10.19 Perf Half Y-21.18%
Book/sh6.05 P/B1.94 EPS next Y-11.20% ROA-28.90% Target Price26.06 Perf Year-55.25%
Cash/sh3.16 P/C3.72 EPS next 5Y1.00% ROE-32.30% 52W Range6.43 - 27.86 Perf YTD-21.18%
Dividend- P/FCF- EPS past 5Y- ROI-27.90% 52W High-57.79% Beta0.49
Dividend %- Quick Ratio12.70 Sales past 5Y- Gross Margin- 52W Low83.04% ATR0.82
Employees334 Current Ratio12.70 Sales Q/Q-99.70% Oper. Margin- RSI (14)63.78 Volatility6.71% 9.11%
OptionableYes Debt/Eq0.00 EPS Q/Q-126.10% Profit Margin- Rel Volume1.32 Prev Close11.51
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume2.17M Price11.76
Recom1.90 SMA2011.81% SMA5031.28% SMA200-10.17% Volume2,802,679 Change2.17%
Jun-03-22Initiated Robert W. Baird Neutral $11
Feb-28-22Reiterated B. Riley Securities Buy $30 → $21
Oct-20-21Initiated Cowen Outperform
Oct-08-21Downgrade Stifel Buy → Hold $44 → $18
Oct-08-21Downgrade Goldman Buy → Neutral $71 → $20
Sep-23-21Upgrade Raymond James Mkt Perform → Outperform
Jun-21-21Resumed Jefferies Buy $53
May-20-21Upgrade Truist Hold → Buy $34 → $41
May-14-21Initiated B. Riley Securities Buy $52
Jan-26-21Upgrade Stifel Hold → Buy $33 → $43
Dec-10-20Resumed H.C. Wainwright Buy $40
Nov-24-20Initiated BofA Securities Buy $41
Oct-23-20Initiated RBC Capital Mkts Outperform $55
Jun-01-20Downgrade Raymond James Outperform → Mkt Perform
May-29-20Reiterated H.C. Wainwright Buy $42 → $55
May-19-20Upgrade ROTH Capital Neutral → Buy $26 → $60
May-15-20Upgrade Guggenheim Neutral → Buy
May-14-20Reiterated H.C. Wainwright Buy $35 → $42
May-14-20Downgrade SunTrust Buy → Hold $29 → $32
Apr-13-20Initiated SunTrust Buy $29
Jun-20-22 03:59PM  
Jun-08-22 08:30AM  
Jun-03-22 11:32AM  
May-19-22 08:30AM  
May-09-22 08:30AM  
May-05-22 02:46PM  
May-04-22 05:15PM  
Apr-28-22 08:30AM  
Apr-27-22 08:30AM  
Apr-14-22 06:00PM  
Apr-13-22 09:00AM  
Apr-12-22 08:30AM  
Mar-25-22 11:30AM  
Mar-23-22 10:12AM  
Mar-21-22 08:10AM  
Mar-18-22 09:15AM  
Mar-16-22 09:21AM  
Mar-15-22 06:17AM  
Mar-11-22 11:27AM  
Mar-10-22 08:30AM  
Mar-01-22 08:30AM  
Feb-24-22 10:37AM  
Feb-23-22 04:02PM  
Feb-16-22 08:30AM  
Feb-08-22 02:38PM  
Feb-04-22 05:38PM  
Feb-01-22 09:38PM  
Jan-31-22 05:38PM  
Jan-26-22 08:30AM  
Jan-21-22 09:10AM  
Jan-14-22 11:23AM  
Jan-12-22 11:09AM  
Jan-11-22 11:11AM  
Jan-10-22 04:30PM  
Jan-04-22 08:30AM  
Dec-15-21 08:30AM  
Dec-13-21 11:00AM  
Dec-01-21 08:30AM  
Nov-12-21 08:30AM  
Nov-09-21 09:15AM  
Nov-05-21 11:19AM  
Nov-04-21 04:02PM  
Nov-01-21 04:57PM  
Oct-28-21 08:30AM  
Oct-15-21 09:00PM  
Oct-14-21 06:52AM  
Oct-13-21 05:15PM  
Oct-12-21 06:07AM  
Oct-11-21 07:52PM  
Oct-08-21 10:08PM  
Oct-07-21 06:11PM  
Sep-20-21 08:30AM  
Sep-03-21 11:31AM  
Sep-01-21 08:30AM  
Aug-13-21 11:38AM  
Aug-12-21 08:30AM  
Aug-07-21 03:03AM  
Aug-05-21 09:57AM  
Aug-04-21 04:02PM  
Aug-03-21 01:25AM  
Aug-02-21 08:30AM  
Jul-27-21 08:30AM  
Jul-21-21 04:32AM  
Jul-12-21 08:30AM  
Jul-01-21 11:25AM  
Jun-30-21 08:30AM  
Jun-21-21 07:00AM  
Jun-07-21 11:11AM  
Jun-04-21 11:31AM  
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WITTE OWEN N.DirectorJun 22Sale11.7610,000117,600233,271Jun 23 04:40 PM
Amado RafaelEVP of R&D and CMOJun 21Sale11.182,00022,360544,257Jun 22 04:47 PM
Amado RafaelEVP of R&D and CMOMay 19Sale7.4011,50085,092546,257May 19 05:40 PM
Amado RafaelEVP of R&D and CMOMar 15Sale7.715,16939,848320,119Mar 17 05:59 PM
MOORE ALISONChief Technical OfficerMar 15Sale7.638,69866,388120,430Mar 17 05:58 PM
SCHMIDT ERIC THOMASChief Financial OfficerMar 15Sale7.6311,46987,551100,546Mar 17 05:58 PM
Chang David DPresident and CEOMar 15Sale7.6523,648180,8792,289,652Mar 17 05:59 PM
Bhavnagri VeerGeneral CounselMar 15Sale7.688,84967,962413,841Mar 17 05:59 PM
Belldegrun ArieDirectorJan 12Buy12.60155,0391,953,491195,039Jan 14 12:02 PM
Kazam Joshua ADirectorJan 12Buy12.6015,000189,000258,885Jan 14 02:13 PM
Amado RafaelEVP of R&D and CMOOct 01Sale24.3511,507280,185323,928Oct 04 05:55 PM
Bhavnagri VeerGeneral CounselSep 15Option Exercise2.275,00011,350426,669Sep 17 04:44 PM
Bhavnagri VeerGeneral CounselSep 15Sale24.775,000123,844421,669Sep 17 04:44 PM
WITTE OWEN N.DirectorSep 09Sale25.545,000127,700221,182Sep 09 05:32 PM
WITTE OWEN N.DirectorAug 20Sale23.4710,000234,700226,182Aug 23 04:22 PM
Bhavnagri VeerGeneral CounselAug 16Option Exercise2.275,00011,350426,353Aug 17 04:05 PM
Bhavnagri VeerGeneral CounselAug 16Sale21.005,000104,994421,353Aug 17 04:05 PM
Bhavnagri VeerGeneral CounselJul 15Option Exercise2.275,00011,350426,353Jul 16 04:14 PM
Bhavnagri VeerGeneral CounselJul 15Sale21.555,000107,753421,353Jul 16 04:14 PM